BNTXBioNTech SESigning up patients
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 558 (planned)
- Started
- Oct 30, 2025
- Main results expected
- Dec 2029
- Fully finished
- Sep 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 32 months
Overall Survival (OS)
Measured over: Up to approximately 49 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07173751 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC